# EU-1-20-1485_public-assessment-report_20201127_20201127_obiltoxaximab-sfl-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES HEALTH
17 September 2020
EMA/524933/2020
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Obiltoxaximab SFL
Common name: obiltoxaximab
Procedure No. EMEA/H/C/005169/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential
nature deleted.
Official address Domenico Scarlattilaan 6 . 1083 HS Amsterdam . The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union
C European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
6
6
1.1. Submission of the dossier.
1.2. Steps taken for the assessment of the product
7
2. Scientific discussion
9
2.1. Problem statement
9
2.1.1. Disease or condition
9
2.1.2. Epidemiology
9
2.1.3. Aetiology and pathogenesis
9
2.1.4. Clinical presentation, diagnosis and prognosis
10
2.1.5. Management
10
2.2. Quality aspects
13
2.2.1. Active Substance
13
2.2.2. Finished Medicinal Product
16
2.2.3. Discussion on chemical, pharmaceutical and biological aspects
20
2.2.4. Conclusions on chemical, pharmaceutical and biological aspects
20
2.3. Non-clinical aspects
20
2.3.1. Introduction
20
2.3.2. Pharmacology
20
2.3.3. Pharmacokinetics
24
2.3.4. Toxicology
26
2.3.5. Ecotoxicity/environmental risk assessment
29
2.3.6. Discussion on non-clinical aspects
29
2.3.7. Conclusion on the non-clinical aspects
31
2.4. Clinical aspects
31
2.4.1. Introduction
31
2.4.2. Pharmacokinetics
32
2.4.3. Pharmacodynamics
47
2.4.4. Discussion on clinical pharmacology.
53
2.4.5. Conclusions on clinical pharmacology
57
2.5. Clinical efficacy
58
2.5.1. Dose selection
61
2.5.2. Main studies
62
2.5.3. Discussion on clinical efficacy
91
2.5.4. Conclusions on the clinical efficacy
93
2.6. Clinical safety
93
2.6.1. Discussion on clinical safety
99
2.6.2. Conclusions on the clinical safety
100
2.7. Risk Management Plan
100
2.8. Pharmacovigilance.
101
2.9. New Active Substance
101
2.10. Product information
102
2.10.1. User consultation
102
2.10.2. Labelling exemptions
102
EMA/524933/2020
Page 2/113
